Samsung Biologics Secures 835.7 Billion Won CMO Contract Increase with US Pharma, Boosting Long-term Revenue Visibility

Samsung Biologics filed a correction to its single sale and supply contract on June 17, 2026, increasing the contract value with a US-based pharmaceutical company from 737.3 billion won to 835.7 billion won, an increase of approximately 98.7 billion won.
The increased contract amount represents 18.38% of its 2024 consolidated revenue of 4.547 trillion won, with the contract running until December 31, 2031.
The contract increase was requested by the customer, reflecting confidence in Samsung Biologics' contract manufacturing capabilities and positively impacting long-term revenue stability.
The counterparty's identity is withheld for business secrecy until December 31, 2031, but being a US pharmaceutical company suggests high credibility.
This disclosure does not involve capital changes or shareholder return policies, and no financial soundness indicators are mentioned.
[AI Summary]Samsung Biologics expanded its long-term order backlog by increasing an existing CMO contract by 13.4%. This demonstrates core business growth without capital dilution, which is favorable for the stock price, but no immediate shareholder return is expected. The undisclosed counterparty introduces slight uncertainty, but it is likely a major US pharma, keeping credit risk low.